EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Decitabine Enhances Sorafenib Sensitivity in Renal Cell Carcinoma by Promoting BIN1 and SYNE1 Expressions

Lijie Kang, Mengyun Jin, Yuqin Mao, Aixiao Xia

Frontiers in Bioscience-Landmark · 2024

DOI: 10.31083/j.fbl2910370 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Frontiers in Bioscience-Landmark, 2024. Verfasst von Lijie Kang und 3 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pharmacy, Shaoxing People's Hospital, 312000 Shaoxing, Zhejiang, China. Hauptthemen laut MEDLINE: Sorafenib, Carcinoma, Renal Cell, Decitabine, Kidney Neoplasms. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 39 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Renal cell carcinoma (RCC), especially clear cell RCC (ccRCC), significantly impacts health, and results in particularly poor outcomes in patients at the advanced stage. Resistance to vascular endothelial growth factor (VEGF) pathway-targeting tyrosine kinase inhibitors (TKIs) is a major barrier in effective ccRCC treatment. Herein, we aim to explore how decitabine mediates bridging integrator 1 (BIN1) and spectrin repeat containing nuclear envelope protein 1 (SYNE1) to impact resistance of ccRCC to sorafenib.

Methods

Employing bioinformatics on datasets GSE64052 and CancerSea, we identified genes linked to TKI resistance, ultimately focusing on SYNE1. We assessed influences of SYNE1 overexpression and BIN1 knockdown via quantitative real-time PCR (qRT-PCR) and Western blot. Assessment of cell viability and apoptosis was accomplished using cell counting kit-8 (CCK-8) assays and flow cytometry. The investigation into the potential interactions between SYNE1 and BIN1, as well as their impacts on sorafenib sensitivity was accomplished by Co-Immunoprecipitation (Co-IP) and Glutathione-S-transferase (GST) Pull-down.

Results

SYNE1 was substantially down-regulated in sorafenib-resistant ccRCC cells, and its overexpression increased sorafenib sensitivity, decreased viability and enhanced apoptosis. Interaction between BIN1 and SYNE1 was confirmed, with BIN1 level lower in resistant cells. BIN1 knockdown reduced the beneficial effects of SYNE1 overexpression on sorafenib sensitivity. Decitabine treatment elevated both SYNE1 and BIN1, while boosting apoptosis and reducing sorafenib resistance.

Conclusions

SYNE1 contributes to the modulation of sorafenib resistance in ccRCC cells through interacting with BIN1. Decitabine treatment enhances expressions of these two proteins to improve TKI response, suggesting a potential strategy for counteracting resistance and bettering patient outcomes.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

SorafenibCarcinoma, Renal CellDecitabineKidney NeoplasmsDrug Resistance, NeoplasmTumor Suppressor ProteinsNuclear ProteinsAdaptor Proteins, Signal TransducingCytoskeletal ProteinsNerve Tissue ProteinsHumansCell Line, TumorApoptosisGene Expression Regulation, NeoplasticAntineoplastic AgentsCell Survival

Stichwörter der Autor:innen

bridging integrator 1clear cell renal cell carcinomadecitabinesorafenibspectrin repeat containing nuclear envelope protein 1

Substanzen

SorafenibDecitabineTumor Suppressor ProteinsNuclear ProteinsAdaptor Proteins, Signal TransducingCytoskeletal ProteinsBIN1 protein, humanNerve Tissue ProteinsSYNE1 protein, humanAntineoplastic Agents

Autor:innen und Institutionen

  • Department of Pharmacy, Shaoxing People's Hospital, 312000 Shaoxing, Zhejiang, China.
  • Department of Pharmacy, Tiantai People's Hospital of Zhejiang Province (Tiantai Branch of Zhejiang Provincial People's Hospital), Hangzhou Medical College, 317200 Taizhou, Zhejiang, China.

Zitieren

APA

Kang, L., Jin, M., Mao, Y., & Xia, A. (2024). Decitabine Enhances Sorafenib Sensitivity in Renal Cell Carcinoma by Promoting BIN1 and SYNE1 Expressions. Frontiers in Bioscience-Landmark. https://doi.org/10.31083/j.fbl2910370

Vancouver

Kang L, Jin M, Mao Y, Xia A. Decitabine Enhances Sorafenib Sensitivity in Renal Cell Carcinoma by Promoting BIN1 and SYNE1 Expressions. Frontiers in Bioscience-Landmark. 2024. doi:10.31083/j.fbl2910370

BibTeX
@article{Kang2024,
  author = {Kang, Lijie and Jin, Mengyun and Mao, Yuqin and Xia, Aixiao},
  title = {Decitabine Enhances Sorafenib Sensitivity in Renal Cell Carcinoma by Promoting BIN1 and SYNE1 Expressions},
  journal = {Frontiers in Bioscience-Landmark},
  year = {2024},
  doi = {10.31083/j.fbl2910370}
}
Kostenlos starten →